PsyRx Advances Clinical Trial Exploration with Successful Completion of Toxicological Safety Study in Rats

TEL AVIV, Israel, March 25, 2024 /PRNewswire/ — PsyRx, a leading innovator in pharmaceutical research, is pleased to announce the successful conclusion of the live phase of a toxicological safety study involving the combined treatment of SSRI plus ibogaine. This groundbreaking study is a…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks